Arbutus Biopharma Corp Segments Disclosure
| Year ended December 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| (in thousands) | |||||||||||
| Revenue | $ | 14,083 | $ | 6,171 | |||||||
| Less: | |||||||||||
| Research and development employee expense, lab supplies and overhead | 13,961 | 26,613 | |||||||||
| Imdusiran IM-PROVE I, II & III clinical trials expense | 4,824 | 15,735 | |||||||||
| AB-101-001 Phase 1a/1b clinical trial expense | 6,220 | 10,196 | |||||||||
| Other early research and development programs expense | 236 | 1,493 | |||||||||
| General and administrative expense | 15,893 | 22,108 | |||||||||
| Restructuring expense | 12,939 | 3,720 | |||||||||
| Other segment expense (1) | (1,747) | 2,811 | |||||||||
| Add: | |||||||||||
| Interest income | 4,068 | 6,585 | |||||||||
| Gain on sale of property and equipment | 674 | — | |||||||||
| Segment net loss | $ | (33,501) | $ | (69,920) | |||||||
| Adjustments and reconciling items | — | — | |||||||||
| Consolidated net loss | $ | (33,501) | $ | (69,920) | |||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 23, 2026 | Showing above |
| 2024 | Mar 27, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.